MGMT methylation as a predictor of efficacy of temozolomide and capecitabine in metastatic colorectal cancer

MD, professor
Per Pfeiffer
Department of Oncology, Odense university Hospital

Projekt styring

Projekt status	Open



Data indsamlingsdatoer
Start	15.01.2025
Slut	01.02.2027

Projektet i tal

OPEN undersøgelse/kliniske data
Forventet # af deltagere	80
Inkluderet antal deltagere





Inkluderede deltagere med prøver
Prøver

MGMT methylation as a predictor of efficacy of temozolomide and capecitabine in metastatic colorectal cancer

Short summary

Between 2013-2016 we treated 82 patients with metastatic colorectal cancer with temozolomide and capecitabine in a phase 2 study. We wish to investigate whether methylation/silencing of the MGMT gene is a predictor for efficacy of this treatment combination, by analyzing archived tumor tissue from the patients in the phase 2 study.

Data and biological material

Data on survival (PFS, OS), adverse events and methylation of MGMT on tumor tissue.

Collaborating researchers and departments

Department of clinical Pahology, Odense University Hospital,